158 related articles for article (PubMed ID: 10052901)
1. Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis.
Dalla Costa T; Nolting A; Kovar A; Derendorf H
J Antimicrob Chemother; 1998 Dec; 42(6):769-78. PubMed ID: 10052901
[TBL] [Abstract][Full Text] [Related]
2. Determination of free extracellular concentrations of piperacillin by microdialysis.
Nolting A; Costa TD; Vistelle R; Rand KH; Derendorf H
J Pharm Sci; 1996 Apr; 85(4):369-72. PubMed ID: 8901070
[TBL] [Abstract][Full Text] [Related]
3. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis.
Tomaselli F; Dittrich P; Maier A; Woltsche M; Matzi V; Pinter J; Nuhsbaumer S; Pinter H; Smolle J; Smolle-Jüttner FM
Br J Clin Pharmacol; 2003 Jun; 55(6):620-4. PubMed ID: 12814459
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment.
Derendorf H; Dalla Costa T
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):482-8. PubMed ID: 8937930
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
Strenkoski-Nix LC; Forrest A; Schentag JJ; Nix DE
J Clin Pharmacol; 1998 Nov; 38(11):1063-71. PubMed ID: 9824789
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
Sörgel F; Kinzig M
Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.
Nau R; Kinzig-Schippers M; Sörgel F; Schinschke S; Rössing R; Müller C; Kolenda H; Prange HW
Antimicrob Agents Chemother; 1997 May; 41(5):987-91. PubMed ID: 9145857
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic characteristics of piperacillin/tazobactam.
Sörgel F; Kinzig M
Intensive Care Med; 1994 Jul; 20 Suppl 3():S14-20. PubMed ID: 7962984
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.
Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
J Antimicrob Chemother; 2001 Aug; 48(2):259-67. PubMed ID: 11481298
[TBL] [Abstract][Full Text] [Related]
13. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.
Sörgel F; Kinzig M
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():39-60. PubMed ID: 8383655
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.
Wise R; Logan M; Cooper M; Andrews JM
Antimicrob Agents Chemother; 1991 Jun; 35(6):1081-4. PubMed ID: 1656853
[TBL] [Abstract][Full Text] [Related]
15. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister PD; Prevan AM; Sanders CC
Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
[TBL] [Abstract][Full Text] [Related]
16. Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.
Auclair B; Ducharme MP
Antimicrob Agents Chemother; 1999 Jun; 43(6):1465-8. PubMed ID: 10348772
[TBL] [Abstract][Full Text] [Related]
17. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.
Incavo SJ; Ronchetti PJ; Choi JH; Wu H; Kinzig M; Sörgel F
Antimicrob Agents Chemother; 1994 Apr; 38(4):905-7. PubMed ID: 8031071
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
19. Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
Dowell JA; Korth-Bradley J; Milisci M; Tantillo K; Amorusi P; Tse S
J Clin Pharmacol; 2001 Sep; 41(9):979-86. PubMed ID: 11549103
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.
Bourget P; Lesne-Hulin A; Le Reveillé R; Le Bever H; Carsin H
Antimicrob Agents Chemother; 1996 Jan; 40(1):139-45. PubMed ID: 8787895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
